PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 67072
Title: The paradox role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis, progress and therapeutic potential

Reviewer’s code: 05048167
Position: Editorial Board
Academic degree: PhD
Professional title: Senior Scientist
Reviewer’s Country/Territory: Germany
Author’s Country/Territory: China
Manuscript submission date: 2021-04-26
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-04-26 09:09
Reviewer performed review: 2021-04-27 14:10
Review time: 1 Day and 5 Hours

Scientific quality
[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good
[ ] Grade D: Fair [ ] Grade E: Do not publish

Language quality
[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection

Conclusion
[ ] Accept (High priority) [ ] Accept (General priority)
[ ] Minor revision [ ] Major revision [ ] Rejection

Re-review
[ ] Yes [ ] No

Peer-review statements
Peer-Review: [ ] Anonymous [ ] Onymous
Conflicts-of-Interest: [ ] Yes [ ] No
SPECIFIC COMMENTS TO AUTHORS
Dear Editor, Dear Authors,

It is promising to have a nice structured review article to summarize the role of IL-33 / ST2 in colorectal cancer prevention, carcinogenesis, progress and their therapeutic potential based on a number of update evidence and studies. However, there are still some major points, which have to be further concerned.

1. It is suggested to incorporate better graphic figures to illustrate both the structure of IL-33 and its ligand ST2 as well as the role of IL-33 / ST2 in CRC carcinogenesis and progression if applicable. For the therapeutic potentials, a comprehensive table to sum up the therapeutic strategies targeting IL-33 / ST2 will be more informative.

2. It is highly important to ask the author to check all the references cited in the manuscript properly. For instance: #In particular, it is worth mentioning that several risk factors are related CRC development, including lack of exercise, smoking, red meat and alcohol consumption [3, 4]. Reference 4 doesn’t mention this point. #Combining radiation with conventional chemotherapy can exacerbate mucositis, leading to chemotherapeutic dose reductions or inevitable cessation of such treatments [49, 50]. It is rather hard to find the correlated description in the reference 49 and 50.

3. In the title there is a focus on colorectal carcinogenesis, progress….but in the content, there is only a part for IL-33 / ST2 and CRC progression, the structure need to be better organized.

4. There are already IL-33 antibody clinical trials, for instance, SAR440340 (Anti-IL-33 mAb) or other blockade strategies could be further discussed in the part of: Diversified therapeutics based on IL-33 / ST2 signaling in CRC.

5. The potential role of IL-33 in regulating tumor initiating cells has been reported, as well as the impact on stem cell–niche interactions. (Taniguchi et al Science 2021), this new highlight could be further integrated into the review, linking to CRC prospects.

Minor pointes: 1. There are still some mistakes about language and typos, the authors are suggested to optimize the manuscript.
completely. The expression like: ‘Generally speaking’, ‘type-II disbetes’, ‘Recent research progress seem to provide’ … in the context, has to be avoided. 2. Be consistent with the space before the citation, some have, some did not have, please update that accordingly. 3. A summary of abbreviations will be appreciated.